Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma.
Caroline E GleasonMark A DicksonMary E Klein DooleyCristina R AntonescuRodrigo Gularte-MéridaMarimar BenitezJuliana I DelgadoRaghu P KataruMark Wei Yi TanMartina BradicTravis E AdamsonKenneth P SeierAllison L RichardsMarta PalafoxEric ChanSandra P D' AngeloMrinal M GounderMary Louise KeohanCiara M KellyPing ChiSujana MovvaJonathan LandaAimee M CragoMark T A DonoghueLi-Xuan QinVioleta SerraMesruh TurkekulAfsar BarlasDaniel M FiresterKatia ManovaBabak J MehraraMarta KovatchevaNguan Soon TanSamuel SingerWilliam D TapAndrew KoffPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Abemaciclib was well tolerated and showed promising activity in DDLS. The discovery of ANGPTL4 as a late regulator of geroconversion helped to define how cellular senescence modulates the immune tumor microenvironment and contributes to both positive and negative clinical outcomes.